Provider of a wide range of genomic services. The company offers gene detection services (diagnosis, prognosis, and recurrence monitoring) for diseases like acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome (MDS), myeloproliferative tumor, genetic testing of blood tumors. Founded in 2017, headquartered in Jinghai, China. The company has raised $14.1M in funding at the series c stage. The team comprises 4 (Jun 30, 2026) employees. Backed by investors including Shangha Founded in 2017, headquartered in Jinghai, China, the company has raised $14.1M in Series C funding. The company operates in the Life Sciences sector. Its business model encompasses Genomics. The company leverages advanced technology to address market needs and deliver innovative solutions to its target customers.
← All startups
ChosenMed
Series CProvider of a wide range of genomic services. The company offers gene detection services (diagnosis, prognosis, and recurrence monitoring) for diseases like acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome (MDS), myeloproliferative tumor, genetic testing of blood tumors. Founded in 2017, headquartered in Jinghai, China. The company has raised $14.1M in funding at the series c stage. The…
About
Business model
Genomics > Genomics Services > Sequencing,
Life Sciences Platforms and Tools > Research Services > Genomics
Institutional investors
Shanghai Alliance Financial Servicesheyahuayi.comHLCMedfine CapitalDelta CapitalYijing CapitalGaoxin KangyangJingming CapitalMifang CapitalXiamen Qianshan Yunfan Asset Management
Latest coverage
📰 See all funding news — keep up with the raises that set comps.
Backed by funds in our directory
🗂️ Explore Life Sciences investors — funds that write checks in this sector.